1029 results about "Ce Antibody" patented technology

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat FGF23 protein and application. The invention provides a monoclonal antibody combination with high specificity and strong sensitivity aiming at cat FGF23 protein. The antibody combination comprises monoclonal antibodies 5A2 and 3A1. By designing and optimizing complementary determining region (CDR) sequences of heavy chain and light chain variable regions, CDR amino acid sequences are respectively shown as SEQ ID NO.1 to SEQ ID NO.12, and the antibody combination has excellent binding activity and detection specificity. A double-antibody sandwich ELISA detection method constructed on the basis of the antibody combination has relatively high sensitivity, and the accuracy of a detection result is remarkably improved.

The invention belongs to the field of antibodies, and particularly relates to an anti-NMP22 monoclonal antibody as well as a preparation method and application thereof. The invention provides CDR sequences of a heavy chain variable region and a light chain variable region of an anti-NMP22 antibody, the antibody can specifically recognize nuclear matrix protein 22 (NMP22), has high affinity and high specificity to the protein, can be applied to diagnosis of diseases related to abnormal urine nuclear matrix protein 22 level, and especially can be applied to clinical diagnosis of bladder cancer.

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

The invention discloses an antibody pair, a reagent and a method for detecting HIV P24, and relates to the field of immunodiagnosis. The antibody pair for detecting the HIV P24 disclosed by the invention comprises the first antibody and the second antibody. The reagent and the detection method based on the antibody pair can accurately detect the existence of the HIV P24.

The invention discloses an anti-PD-L1 antibody coupling drug and a preparation method thereof, belongs to the field of biological medicines, and is used for preparing anti-cancer drugs. The antibody coupling medicine is formed by coupling an anti-PD-L1 antibody and a payload through a linker, a light chain variable region sequence of the antibody is a sequence recorded by SEQ ID NO: 1, a heavy chain variable region sequence of the antibody is a sequence recorded by SEQ ID NO: 2, the payload is an avixatecan derivative Dxd, and the ratio (DAR) of the payload to the antibody is 6-8. The antibody-conjugated drug has a better killing effect on PD-L1 positive tumor cells of human and dogs, and has fewer dimers and higher thermal stability at a high DAR value (DAR6-8), and an accelerated stability test shows that the antibody-conjugated drug has good structural stability and binding activity.

This invention belongs to the field of biological detection technology, specifically relating to a monoclonal antibody combination for detecting feline NT-proBNP protein and its applications. The monoclonal antibody combination of the present invention comprises monoclonal antibodies 3A6 and 5H5. These two antibodies possess unique heavy and light chain variable region complementarity-determining regions, respectively, and their amino acid sequences have been fully defined (SEQ ID NOs. 1-12). This antibody combination can specifically recognize and efficiently bind to feline NT-proBNP protein, making it suitable for the development of a highly sensitive and specific diagnostic tool for feline cardiomyopathy. By constructing a double-antibody sandwich ELISA assay system, the minimum detection limit can reach 100 pg / mL, and it exhibits excellent specificity and stability.

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

To provide a modified antibody of class IgG for use in radioimmunotherapy.SOLUTION: An anti-PSMA antibody comprises a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of the antibody for the neonatal Fc receptor (FcRn), thereby reducing the serum half-life of the modified antibody compared to a wild-type antibody of class IgG. The one or more amino acid modifications having the effect of reducing FcRn binding are selected from positions His310, His433, His435, His436, and Ile253. The antibodies of the present invention are particularly suited for use in radioimmunotherapy.SELECTED DRAWING: None

The present disclosure relates HER2 antibodies and to the de novo design of structure-based design targeted antibodies. According to the current disclosure, computer-implemented methods of designing an antibody sequences that will bind the HER2 with significant affinity at a target receptor epitope are disclosed. The method utilizes artificial intelligence (Al) and machine learning (ML) models that are trained to predict improved biomolecule (e.g., antibody or antibody fragments) binding sequences or other desirable properties using known biomolecule / binding partner complexes. A designed HER2 antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

The invention discloses an antibody or an antigen binding fragment thereof and a related product and application thereof, and relates to the field of immunodetection, the antibody comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is shown as SEQ ID NO: 28 and LCDR1, LCDR2 and LCDR3 in a light chain variable region of which the amino acid sequence is shown as SEQ ID NO: 29, the antibody can be specifically combined with HPV18 type E6-E7 fusion protein, and the antibody can be used for detecting the HPV18 type E6-E7 fusion protein. The method has the advantages of high detection sensitivity, good specificity, high accuracy, good repeatability and the like, and provides a way for effective detection of the HPV18 type E6-E7 fusion protein.

The present invention relates to a nanobody or antigen-binding fragment thereof that specifically binds to serum albumin, a derivative comprising the nanobody or the antigen-binding fragment thereof, a nucleic acid encoding the antibody or antigen-binding fragment thereof, a host cell comprising same, and related uses. Further, the present invention relates to therapeutic use of the antibody or the antigen-binding fragment thereof or the derivative.

Provided are antibodies against DLL3, antibody-drug conjugates comprising the antibodies, and methods of diagnosis and treatment of diseases associated with the expression of DLL3, such as cancer.

There is provided an antibody or fragment thereof wherein the antibody comprises: (a) a heavy chain variable region (VH) wherein the VH comprises a complementarity determining region (CDR) selected from the group consisting of (i) H-CDR1, H-CDR2 and H-CDR3 as shown in any one of SEQ ID NO.1 to 24 or 49 to 88, respectively, and / or (b) a light chain variable region (VL) wherein the VH comprises a complementary determining region (CDR) selected from the group consisting of: (i) H-CDR1, H-CDR2 and H-CDR3 as shown in any one of SEQ ID NO.1 to 24 or 49 to 88; wherein the VL comprises a complementarity determining region (CDR) selected from the group consisting of: (i) L-CDR1, L-CDR2, and L-CDR3 as shown in any one of SEQ ID NO.25 to 48 or 89 to 128, respectively. Preferably, both VH and VL chains are used. Antibodies and fragments thereof have utility in the treatment of cancer.

Provided are an anti-DLL3 antibody, an antibody-drug conjugate comprising the antibody, and a diagnosis and treatment method for a disease related to expression of DLL3, such as cancer.

The invention relates to the technical field of antibodies, in particular to an anti-African swine fever virus p30 protein monoclonal antibody and application thereof, and the anti-African swine fever virus p30 protein monoclonal antibody can be specifically combined with African swine fever virus p30 protein. The anti-ASFV p30 protein monoclonal antibody is prepared by immunizing a BALB / c mouse through an immunological method, and the antibody is high in specificity, titer and affinity and can be applied to immunological detection or antibody detection kits.

The invention relates to the technical field of livestock immunology, in particular to a mouse anti-bovine IgG monoclonal antibody and application thereof. The mouse anti-bovine IgG monoclonal antibody provided by the invention can be specifically combined with bovine IgG, has no cross reaction with other similar proteins, has relatively high affinity with bovine IgG, and has relatively high stability; based on the antibody, a double-antibody sandwich ELISA method for detecting bovine IgG has high sensitivity, specificity and accuracy, accurate and high-throughput detection of the IgG content in bovine serum or other serum analogues or products containing bovine IgG can be realized, and the antibody has a good application prospect in bovine IgG detection.

This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.

The present application belongs to the technical field of biomedicine, and more particularly, relates to an antibody or an antigen-binding fragment thereof capable of specifically binding to p-tau 217, and a multi-specific molecule, a pharmaceutical composition, and a kit comprising same. The present application further relates to use of the antibody or antigen-binding fragment thereof in preparing a kit or a drug. A monoclonal antibody (for example, 2A7 antibody) according to the present application has a high clinical application value in the detection and prevention of AD and the treatment of AD and other tau protein diseases.

The monoclonal antibody of the glycoprotein Gn of the severe fever with thrombocytopenia syndrome virus is screened on the basis of immune repertoire sequencing, and the biological characteristics of the monoclonal antibody are identified. The method comprises the following steps: taking purified SFTSV-Gn as bait, taking virus specific B cells from an immunized female BALB / c mouse B cell bank, selecting an antibody sequence with potential binding activity by utilizing a 10 * immune repertoire sequencing method in combination with bioinformatics analysis, constructing the antibody sequence to an eukaryotic expression vector pcDNA3.4, expressing and purifying a monoclonal antibody, and identifying the biological activity of the monoclonal antibody. 14 antibodies are selected from 3544 captured B cells, functional verification shows that 12 antibodies can be combined with SFTSV-Gn glycoprotein, and the Gn-5 antibody and the Gn-7 antibody have high combining capacity; western blot, indirect immunofluorescence test and flow cytometry prove that the antibody can specifically recognize the SFTSV, the effective concentration is as low as 2 mu g / mL, and a foundation is laid for development of a rapid diagnosis reagent for the SFTSV.

Provided is the development and use of a novel immunomodulator. The immunomodulator is an antibody or an antigen-binding portion thereof that binds to CCR8. The antibody has a neutralizing activity in blocking CCL1 / CCR8 axis, can inhibit CCL1-induced cell activation, and for low-affinity FcγRIIIA158F allele carriers in the population, enhances the ADCC effect by means of Fc optimization.

The invention relates to the technical field of biomedicine, in particular to a C1q antibody and application thereof, and a medicament for inhibiting classical pathway activation of complement and application thereof. The C1q antibody comprises a VHCDR1, a VHCDR2 and a VHCDR3 of which the amino acid sequences are shown as SEQ ID NO: 1 to SEQ ID NO: 3, and a VLCDR1, a VLCDR2 and a VLCDR3 of which the amino acid sequences are shown as SEQ ID NO: 4 to SEQ ID NO: 6. The antibody has good affinity with C1q antigen, and can effectively inhibit classical pathway activation of complement.

The present invention relates to an antibody or an antigen-binding fragment thereof binding to CLDN18.2, an antibody-drug conjugate comprising same, and a use of the antibody and the antibody-drug conjugate. An anti-CLDN18.2 monoclonal antibody according to the present invention comprises a fully human antibody sequence, thereby having low in vivo immunogenicity, and exhibits excellent antigen affinity and binding ability specific to a low expression to a high expression level of the CLDN18.2 protein. Thus, the antibody is expected to exhibit high specificity and safety as an antibody-based therapeutic agent such as in the form of a monoclonal antibody and / or an antigen-binding fragment (scFv), an antibody-drug conjugate (ADC), an immune cell engager, a chimeric antigen receptor (CAR), a multispecific antibody, and the like. In addition, the antibody according to the present invention may undergo cellular internalization, enables an anti-CLDN18.2 antibody-drug conjugate comprising said antibodies to be conveniently prepared, and has excellent yield and quality and thus is expected to be highly likely to be developed as a drug. A drug conjugate comprising the anti-CLDN18.2 antibody according to the present invention has excellent in vivo anticancer efficacy and has an expanded therapeutic index (TI) and thus is expected to be usefully employable for the treatment and / or prevention of cancer diseases expressing CLDN18.2 and related diseases.

The present invention provides an antibody composition for detecting multiple myeloma based on full-spectrum flow cytometry and its application, belonging to the technical field of multiple myeloma detection. The antibody composition includes CD3 antibody, CD20 antibody, HLA-DR antibody, CD8 antibody, CD11b antibody, CD10 antibody, CD71 antibody, CD28 antibody, CD14 antibody, CD13 antibody, Igκ antibody, CD15 antibody, Igλ antibody, CD117 antibody, CD56 antibody, CD45 antibody, CD19 antibody, CD34 antibody, CD138 antibody, CD4 antibody, CD38 antibody, CD22 antibody and CD27 antibody. The kit containing the antibody composition can be applied to a full-spectrum flow cytometer to accurately perform preliminary screening on patients with multiple myeloma.

The present invention relates to antibody-cytokine conjugates, wherein the cytokine is conjugated to the antibody via a cleavable linker. Conjugates according to the invention can be prepared by coupling a functionalized antibody Ab (F) x comprising x reactive moieties F, where x is an integer in the range of 1-10, with an immune cell-binding polypeptide comprising one or two reactive moieties Q, where the antibody is specific for tumor cells, and the immune cell-binding polypeptide is specific for immune cells, wherein the reaction forms a covalent bond between the functionalized antibody and the immune cell-binding polypeptide by reaction of Q with F. The invention further relates to antibody-cytokine conjugates obtainable by the method according to the invention and to medical uses thereof.

Provided is an anti-CLL1 antibody and an application thereof. The variable region of the anti-CLL1 antibody includes the CDRs of SEQ ID NO: 1 to 6, SEQ ID NO: 5, and SEQ ID NO: 7 to 11 or SEQ ID NO: 12 to 17. The anti-CLL1 antibody of the present application has significant binding ability to both free and cell surface CLL1. After humanization, the affinity of the antibody to CLL1 is further improved, and it has important application prospect in the clinical diagnosis and / or treatment of tumors.

The present invention discloses CLDN18.2-targeting antibodies, bispecific antibodies and use thereof. The CLDN18.2-targeting antibody is a single-domain heavy-chain antibody that has high affinity for tumor cells endogenously expressing CLDN18.2 and can induce high endocytic activity. The bispecific antibody can target CLDN18.2 and CD3 and retains the binding effect of an Fc to an FcRn; meanwhile, a mutant Fc is preferred so as to reduce the binding to an FcgR and thus the activation of non-specific T cells caused by the cross-linking of an FcgR. The CD3-terminus activity is optimized so that the release of common cytokines in CRS, such as IL6 and TNFα can be reduced.

The invention relates to an AFP specific binding protein and a preparation method and application thereof in the technical field of immunodetection. The AFP specific binding protein has an AFP binding structural domain a or / and an AFP binding structural domain b; the AFP binding structural domain a comprises VH CDR1-3 as shown in a sequence SEQ ID NO. 7 to 9 and VL CDR1-3 as shown in a sequence SEQ ID NO. 10 to 12; the AFP binding structural domain b comprises VH CDR1-3 as shown in a sequence SEQ ID NO. 13-15, VH CDR1-3 as shown in a sequence SEQ ID NO. 16-18 of the VL CDR1-3 is shown as the sequence SEQ ID NO. 16-18 of the VL CDR1-3. Compared with the prior art, the invention provides a novel anti-AFP antibody, the effective detection of AFP can be realized by adopting the antibody, and a novel scheme is provided for the detection of AFP.

The invention relates to an anti-canine IL-31 antibody or an antigen binding part thereof and application thereof, and belongs to the technical field of antibody preparation. The invention relates to an anti-canine interleukin-31 antibody or an antigen binding part thereof, amino acid for coding the antibody or the antigen binding part thereof, polynucleotide, a carrier containing the polynucleotide, a host cell containing the polynucleotide or the carrier, a method for preparing and purifying the antibody and application of the antibody or the antigen binding part thereof. The anti-canine IL-31 antibody disclosed by the invention can be specifically combined with a canine IL-31 antigen, and can effectively relieve symptoms such as pruritus, allergy, nasal polyp or asthma and the like. The mutated anti-canine IL-31 antibody also has a corresponding function of combining with the antigen canine IL-31, and also can be used for treating IL-31 related diseases.